Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Tirzepatide-based evidence from the SURPASS (Researching Tirzepatide in Patients with Type 2 Diabetes for Glycemic Control and Weight Management) trials (SURPASS-1 NCT03954834 and SURPASS-5 NCT04039503) demonstrated dose-dependent, significant weight loss over 40 weeks compared with placebo, along with reductions in BMI and waist circumference [62, 63]
Accessed: Apr
Please keep in mind, if you refill your current medication on or after 7/1/2025, youll need to pay the full cost. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark, along with a few other medications that are generally less effective
10.2174/187220809789389135 Recent Pat
Judicial Panel on Multidistrict Litigation consolidated 78 Depo-Provera lawsuits before one judge in Florida
